Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06579248 · ClinicalTrials.gov registry record · Early Phase 1

Intraoral Hypothermia Device for Preserving Taste During Radiation

A Early Phase 1 study of Head and Neck Cancer and Radiation Therapy, sponsored by Henry Ford Health System.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
1
Study location

NCT06579248: Recruiting Early Phase 1 study of Head and Neck Cancer and Radiation Therapy, sponsored by Henry Ford Health System.

NCT06579248 is a Early Phase 1 study of Head and Neck Cancer and Radiation Therapy that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 15 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06579248, a Early Phase 1 study of Head and Neck Cancer and Radiation Therapy, is actively recruiting participants, sponsored by Henry Ford Health System.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.

Primary Outcome

Taste will be measured objectively using Burghart taste strips in five different concentrations of salty, sweet, sour, bitter, and umami. Taste will be assessed on a yes/no scale to reflect the ability to correctly identify taste category. Taste will be measured subjectively with a series of previously-validated, patient-reported taste-related questions. The questions comprise of a modified Chemotherapy-induced Taste Alteration Scale (CiTAS), one question from the Head and Neck Quality of Life

Interventions

  • DEVICE Intraoral Device

Study Locations (1)

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-11-12
Est. Completion 2026-08-30
Phase Early Phase 1
Henry Ford Health System

234 total trials

What NCT06579248 shows while recruiting

NCT06579248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (94% lower).

The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Intraoral Device is the first listed.

NCT06579248 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT06579248 about?

NCT06579248 is a clinical study titled "Intraoral Hypothermia Device for Preserving Taste During Radiation". Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatm...

What is the current status of trial NCT06579248?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2024-11-12. Estimated completion is 2026-08-30.

What conditions does trial NCT06579248 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Radiation Therapy, Taste Dysfunction.

What interventions are being tested in trial NCT06579248?

The interventions under investigation include: Intraoral Device (DEVICE).

Who is sponsoring clinical trial NCT06579248?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06579248 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06579248's enrollment target sits among peer trials

15 227th of 250 higher than 22 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06579248, the US trial registry maintained by the National Library of Medicine. NCT06579248 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.